219 related articles for article (PubMed ID: 26912326)
1. The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study.
Singh R; Bemelman FJ; Hodiamont CJ; Idu MM; Ten Berge IJ; Geerlings SE
BMC Infect Dis; 2016 Feb; 16():90. PubMed ID: 26912326
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study.
Chen RY; Li DW; Wang JY; Zhuang SY; Wu HY; Wu JJ; Qu JW; Sun N; Zhong C; Zhu C; Zhang M; Yu YT; Yuan XD
Int J Infect Dis; 2022 Dec; 125():209-215. PubMed ID: 36243280
[TBL] [Abstract][Full Text] [Related]
3. Higher risk of urinary tract infections in renal transplant recipients receiving pentamidine versus trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis pneumonia prophylaxis.
Fu W; Barahona M; Harkness T; Cohen E; Reardon D; Yoo PS
Clin Transplant; 2020 Nov; 34(11):e14067. PubMed ID: 32810885
[TBL] [Abstract][Full Text] [Related]
4. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
McLaughlin MM; Galal A; Richardson CL; Sutton SH; Barr VO; Patel N; Mitchell P; Stosor V
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28833985
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety evaluation of thrice weekly double strength vs daily single strength trimethoprim-sulfamethoxazole for prophylaxis of pneumocystis jirovecii pneumonia after kidney transplantation: a two year prospective cohort study.
Yang H; Pang L; Hu X; Wang W; Xu B; Zhang X; Liu L
J Pharm Pharm Sci; 2021; 24():220-226. PubMed ID: 33956598
[TBL] [Abstract][Full Text] [Related]
6. Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.
Zmarlicka M; Martin ST; Cardwell SM; Nailor MD
Prog Transplant; 2015 Sep; 25(3):210-6. PubMed ID: 26308779
[TBL] [Abstract][Full Text] [Related]
7. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
Awad M; Sierra CM; Mesghali E; Bahjri K
J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
[TBL] [Abstract][Full Text] [Related]
8. Impact of prophylaxis choice on risk of pneumocystis pneumonia in children with cancer: A case-control study.
Geerlinks AV; Campigotto A; Science M; Gupta S
Eur J Cancer; 2020 Nov; 140():71-75. PubMed ID: 33059195
[TBL] [Abstract][Full Text] [Related]
9. Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant.
Chapman FA; Dickerson JE; Daly C; Clancy M; Geddes C
Ann Transplant; 2019 Dec; 24():625-630. PubMed ID: 31806862
[TBL] [Abstract][Full Text] [Related]
10. Combination of Echinocandins and Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jiroveci Pneumonia After Heart Transplantation.
Lu YM; Lee YT; Chang HC; Yang HS; Chang CY; Huang CM; Wei J
Transplant Proc; 2017 Oct; 49(8):1893-1898. PubMed ID: 28923644
[TBL] [Abstract][Full Text] [Related]
11. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
Urbancic KF; Pisasale D; Wight J; Trubiano JA
Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis of urinary tract infection in persons with recent spinal cord injury: a prospective, randomized, double-blind, placebo-controlled study of trimethoprim-sulfamethoxazole.
Gribble MJ; Puterman ML
Am J Med; 1993 Aug; 95(2):141-52. PubMed ID: 8356980
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study.
Park SY; Jung JH; Kwon H; Shin S; Kim YH; Chong YP; Lee SO; Choi SH; Kim YS; Woo JH; Kim SH; Han DJ
Transpl Infect Dis; 2020 Apr; 22(2):e13245. PubMed ID: 31943590
[TBL] [Abstract][Full Text] [Related]
15. Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab.
Park JW; Curtis JR; Jun KI; Kim TM; Heo DS; Ha J; Suh KS; Lee KW; Lee H; Yang J; Kim MJ; Choi Y; Lee EB
Chest; 2022 May; 161(5):1201-1210. PubMed ID: 34788668
[TBL] [Abstract][Full Text] [Related]
16. High daily doses of trimethoprim/sulfamethoxazole are an independent risk factor for adverse reactions in patients with pneumocystis pneumonia and AIDS.
Chang HM; Tsai HC; Lee SS; Kunin C; Lin PC; Wann SR; Chen YS
J Chin Med Assoc; 2016 Jun; 79(6):314-9. PubMed ID: 27025225
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of effectiveness, hyperkalaemia, and hepatotoxicity of trimethoprim-sulphamethoxazole prophylaxis for Pneumocystis jirovecii pneumonia in paediatric patients: A single-centre retrospective study.
Kato H; Hagihara M; Asai N; Mikamo H; Iwamoto T
Int J Antimicrob Agents; 2024 May; 63(5):107151. PubMed ID: 38508538
[TBL] [Abstract][Full Text] [Related]
18. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study.
Yamashita K; Shimomura Y; Ikesue H; Muroi N; Yoshimoto A; Hashida T
BMC Infect Dis; 2021 Jul; 21(1):664. PubMed ID: 34238239
[TBL] [Abstract][Full Text] [Related]
20. Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality.
Song S; Zhang Y; Yu J; Xie C; Chen Y; Zhang X
BMC Infect Dis; 2022 Dec; 22(1):961. PubMed ID: 36575406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]